Pfizer (NYSE:PFE) Sets New 12-Month High on Analyst Upgrade

Key Points

• Pfizer shares reached a new 52-week high, trading as high as $31.44 after UBS raised its price target from $27 to $30, while maintaining a neutral rating.
• Pfizer beat quarterly earnings and revenue estimates and raised its 2026 revenue and adjusted EPS forecasts. Growth in newer and non-COVID products was positive, though declining COVID sales and margin pressure remain challenges.
• Analyst sentiment is mixed: MarketBeat data showed an average “Hold” rating and a $29.81 average price target, while Scotiabank raised its target to $35 and reiterated “sector outperform.”

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price hit a new 52-week high on Thursday after UBS Group raised their price target on the stock from $27.00 to $30.00. UBS Group currently has a neutral rating on the stock. Pfizer traded as high as $31.44 and last traded at $31.2880, with a volume of 8,851,793 shares changing hands. The stock had previously closed at $30.79.

A number of other analysts have also recently weighed in on PFE. BMO Capital Markets lowered their target price on shares of Pfizer from $34.00 to $30.00 and set an "outperform" rating on the stock in a research note on Monday, July 13th. HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, September 10th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, October 13th. Finally, Scotiabank lifted their price objective on shares of Pfizer from $33.00 to $35.00 and gave the stock a "sector outperform" rating in a research note on Wednesday. Five research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $29.81.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat Q3 earnings and revenue expectations and raised its 2026 forecast to $62–$64 billion in revenue and adjusted EPS of $2.95–$3.05. Launched and acquired products grew 32% operationally, while non-COVID products rose 7%. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Scotiabank raised its price target to $35 and reiterated “sector outperform,” adding to the positive outlook surrounding the results. Scotiabank analyst recommendations
• Positive Sentiment: A recent TipRanks article described Pfizer’s dividend as well-covered and the stock’s valuation as modest, potentially appealing to income-focused investors. Article: Pfizer Stock Looks Attractive for Income Investors
• Neutral Sentiment: Analyst views remain mixed: RBC raised its target to $28 and UBS and Citi to $30, but all maintained neutral or sector-perform ratings—targets below the price cited in the reports. RBC analyst recommendations
• Negative Sentiment: Revenue was roughly flat as COVID product sales continued to decline, and margin pressure remains a concern. Pfizer must sustain growth in newer products and deliver on cost savings and pipeline milestones to make the raised outlook durable. Article: Pfizer Just Raised Guidance. The Bigger Test Comes Next

Institutional Investors Weigh In On Pfizer

Large investors have recently added to or reduced their stakes in the business. Retirement Wealth Solutions LLC raised its stake in shares of Pfizer by 144.6% during the 3rd quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 509 shares during the period. Keb Asset Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $26,000. Field & Main Bank purchased a new position in shares of Pfizer in the second quarter valued at $27,000. Bullseye Investment Management LLC purchased a new position in Pfizer during the 2nd quarter valued at about $28,000. Finally, Timbuktu Capital Management LLC purchased a new stake in shares of Pfizer in the second quarter worth $29,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 1.5%

The stock has a market cap of $178.09 billion, a P/E ratio of 44.58, a P/E/G ratio of 2.04 and a beta of 0.31. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock has a 50-day moving average price of $28.69 and a 200-day moving average price of $26.86.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts' consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to analyst estimates of $15.85 billion. Pfizer had a net margin of 6.34% and a return on equity of 19.98%. The business's revenue for the quarter was down .4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.87 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 annualized dividend and a dividend yield of 5.5%. Pfizer's dividend payout ratio (DPR) is 226.32%.

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company's portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.